Taisho Pharmaceutical Holdings
VC Fund
Tokyo, Japan
Taisho Pharmaceutical Holdings is a producer of generic drugs. They mainly manufacture and sell general cold medicines, allergy drugs, lipovitan series, pabron series, tempra, and more.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Taisho Pharmaceutical Holdings invests in
Stages Taisho Pharmaceutical Holdings invests in
Countries Taisho Pharmaceutical Holdings invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2.1M–$12M
- Series C
- $2.3M–$100M
Investment Focus
Industry
- Health Care 6 (50%)
- Biotechnology 3 (25%)
- Medical 2 (17%)
- Wearables 2 (17%)
- Manufacturing 2 (17%)
Stage
- Series A 5 (42%)
- Series C 2 (17%)
- Seed 1 (8%)
- Series B 1 (8%)
- Series D 1 (8%)
Country
- Japan 6 (50%)
- United States 2 (17%)
- Israel 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Akira Uehara
Chairman, President, and CEO
|
Chairman, President, and CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M / Venture - Series Unknown / Apr 04, 2024 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M / Series D / Apr 04, 2024 | |
VIE STYLE
|
VIE STYLE offers wearable music device and AI technology services. | $2.1M / Series A / Mar 07, 2024 | |
Linqmed
|
Linqmed is a pharmaceutical company that specializes in the research and development of radiopharmaceuticals for cancer treatment. | $4.8M / Series A / Dec 22, 2023 | |
AuB
|
AuB is an intestinal microflora analysis that contributes to the athlete's performance improvement and human health maintenance. | $2.3M / Series C / Jun 01, 2022 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series B / Nov 02, 2021 | |
Moodify
|
Moodify transforms the way scents are made to make better, more effective and sustainable consumer products, making the design and manufacturing faster, more scalable, accurate, cost effective and compliant. This, by harnessing 15 years of neuroscience research by the Weizmann Institute, together with cutting edge bioinformatics machine learningtechnologies. | $8M / Series A / Aug 19, 2021 | |
Edifice Health
|
Edifice Health is a spin-out company from a 10-year research study on immune profiling from Stanford University, the Stanford 1,000 Immunomes Project. The technology is the first biomarker composite scoring system to measure immune health and the Inflammatory Age® of an individual which predicts the onset of multiple chronic diseases and providescomprehensive health insights designed to help people change the course of their aging process. | $12M / Series A / Apr 22, 2021 | |
Aiwell
|
Aiwell is a medical and health company that provides health information and the provision of health promotion and prevention services. | Series A / Jul 29, 2020 | |
| See all 12 investments → | |||
Co-Investors
Aphelion Capital
4 deals together
RiverVest
4 deals together
Alpha Wave Ventures
3 deals together
AXA Investment Managers
3 deals together
Features Capital
3 deals together
Senvest Management
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Taisho Pharmaceutical Holdings invest in?
Taisho Pharmaceutical Holdings invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Taisho Pharmaceutical Holdings's check size?
Taisho Pharmaceutical Holdings typically joins rounds of $2.1M–$12M at Series A and $2.3M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taisho Pharmaceutical Holdings participates in.
How do I contact Taisho Pharmaceutical Holdings?
Public channels for Taisho Pharmaceutical Holdings include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Taisho Pharmaceutical Holdings?
The team at Taisho Pharmaceutical Holdings includes Akira Uehara (Chairman, President, and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
